Skip to content

surgical treatment of laryngeal cancer

Middle frontal horizontal partial laryngectomy(MFHPL): a treatment for Stage T1b squamous cell carcinoma of the glottic larynx involving anterior vocal commissure

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12612000443897
Enrollment
60
Registered
2012-04-18
Start date
1996-03-03
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The clinical efficiency of current treatments for T1b laryngeal cancer involving AVC is not satisfactory. Clinical trial about MFHPL and AFVPL were carried out to improve the efficiency of these patients. Both MFHPL and AFVPL could treat these patients effectively. however, MFHPL preserved an intact laryngeal framework, decreased the laryngeal wound, reduced the occurrence of laryngeal stenosis and improved the voice quality post surgery.The postoperative complications, glottic reconstruction, recurrence rate, voice quality and survival rates were evaluated and compared between two treatments.

Interventions

Patients of T1b laryngeal cancer involving anterior vocal commissure(AVC) were treated with middle frontal horizontal partial laryngectomy(MFHPL) or anterior frontal vertical partial laryngectomy (AFVPL) . MFHPL: A window of cartilage was made by cuts from upper 1/3 (about 0.5 cm to the superior aspect of the cartilage) and lower 1/3 (about 0.5 cm to the inferior aspect of the cartilage) in the midline to the middle of the posterior aspects of the cartilage. Larynx was then entered by transecti

Patients of T1b laryngeal cancer involving anterior vocal commissure(AVC) were treated with middle frontal horizontal partial laryngectomy(MFHPL) or anterior frontal vertical partial laryngectomy (AFVPL) . MFHPL: A window of cartilage was made by cuts from upper 1/3 (about 0.5 cm to the superior aspect of the cartilage) and lower 1/3 (about 0.5 cm to the inferior aspect of the cartilage) in the midline to the middle of the posterior aspects of the cartilage. Larynx was then entered by transecting the intralaryngeal mucosa/muscles through one of the cartilage incisions that was farther from the AVC, based on the anatomical relationship between the AVC and cartilage indicated by CT. The tumor was then resected under direct vision with tumor free margins of over 5 mm. Stitches entered at the upper cartilage lamina and came out at the lower vestibular mucosa, then entered at the lower aspect of thyroid cartilage lamina and came out at the subglottic mucosa. These four stitches were aligned and tied to close the larynx. AFVPL:The vertical outline was made along the anterior aspect of the thyroid lamina with 3-5 mm deviation towards the less involved side, and approximately 8-12 mm deviation towards the more severely involved side. A vertical incision was made with a saw on bilateral thyroid laminas. The laryngeal cavity was visualized and approached through the less involved side. The true and false cords interior to the frontolateral thyroid cartilage were resected along with subglottic soft tissues, with tumor margins of over 5 mm. Depending on the extent of the laryngeal defects, the laryngeal cavity was closed directly or reconstructed using sternohyoid myofascia (single or double pedicles), or sternohyoid perichondrium. Both AFVPL and MFHPL are about 1 and a half hours procedure, performed once only. The postoperative complications, voice quality and survival rates were evaluated and compared .

Sponsors

Lei wenbin
Lead SponsorIndividual

Study design

Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

Patients with stage T1bN0M0 early glottic carcinoma and anterior commissure involvement were investigated in our studies. All diagnoses were confirmed as squamous carcinoma by biopsies.

Exclusion criteria

Patients with TNM stages other than T1bN0M0 were excluded.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026